Repeat fasting lipid profile to confirm in 1-2 weeks

Slides:



Advertisements
Similar presentations
Cardiovascular Risk Assessment
Advertisements

SHAHKUR SHABIR GP REGISTRAR DR ELLA RUSSELL -GP TRAINER SUNNYBANK MEDICAL CENTRE OCT 2011.
M ETABOLIC S YNDROME IN P ERIONIAL D IALYSIS Dr. Sreelatha Calicut.
10 Points to Remember for the Management of Overweight and Obesity in Adults Management of Overweight and Obesity in Adults Summary Prepared by Elizabeth.
ATP III Guidelines Specific Dyslipidemias. 2 Specific Dyslipidemias: Very High LDL Cholesterol (  190 mg/dL) Causes and Diagnosis Genetic disorders –Monogenic.
CKD In Primary Care Dr Mohammed Javid.
Chronic Kidney Disease NICE Guidelines 2008 Dr Jennifer Kuo Dr Naeema Rashid Dr Shamita Das.
CVD risk estimation and prevention: An overview of SIGN 97.
Canadian Diabetes Association Clinical Practice Guidelines Dyslipidemia Chapter 24 G. B. John Mancini, Robert A. Hegele, Lawrence A. Leiter.
JBS2 Some highlights from the JBS2 guidelines on prevention of cardiovascular disease in clinical practice Jim McMorran GP trainer Visiting Senior Clinical.
Lipids 101 Cardiology Board Review Med-Peds Style!
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.
BHS Guidelines for the management of hypertension BHS IV, 2004 and Update of the NICE Hypertension Guideline, 2006 Guidelines for management of hypertension:
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.
FATS4 Linking cases to the guideline Jane S Skinner Consultant Community Cardiologist.
Professor Julia Hippisley-Cox University of Nottingham.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Department of Family & Community Medicine
METABOLIC SYNDROME Dr Gerhard Coetzer. Complaint Thirsty all the time Urinating more than usual Blurred vision Tiredness.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Rapid E clinical guidance in the management of Type 2 diabetes New Zealand Guidelines Group.
Diabetes in the 21 st Century 2010 Update. American Diabetes Association 2010 Guidelines – Diagnostic Criteria A1C > or = 6.5% is included as diagnostic.
Risk estimation and the prevention of cardiovascular disease SIGN 97.
Improving the Quality of Physical Health Checks
Improving the Quality of Physical Health Checks Kate Dale, Mental/Physical Health Lead BDCT.
SHEFFIELD GUIDELINES: RENAL DISEASE IN DIABETES Dr Jenny Stephenson GP, Stannington Medical Centre
VA/DoD 2006 Clinical Practice Guideline For Screening and Management of Overweight and Obesity Guideline Summary: Key Elements.
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
Blood pressure control in primary health care WORKSHOP
Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.
Hypertension NICE CG127 August Hypertension is not a disease it is a risk factor for cardiovasuclar disease (CVD)-it is a modifiable risk factor.
Hypertension Dr Nidhi Bhargava 8/10/13. Why Treat Increased risk of cardiovascular death and mortality Increased systolic, diastolic and pulse pressures.
A persistent elevation in blood pressure that is over 140 / 90 mmHg for more than 3 months, which will Not respond to non pharmacological treatment (
Section IV. Routine and Optional Laboratory Tests for the Investigation of Patients with Hypertension 2015 Canadian Hypertension Education Program Recommendations.
Paul Zimmet & George Alberti
The Hyperlipidaemias What are they and how to treat Dr John O’Donnell Consultant Clinical Biochemist Borders General Hospital.
CDA exercise guidelines 150 minutes moderate – intensity (60 – 70% of max) aerobic over minimum 3 non consecutive days PLUS resistance exercise 3.
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Laboratory Testing For Cardiovascular Risk
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.
Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.
A two stage screening process – the pre-diabetes pathway.
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
An audit of non-HDL cholesterol reporting
Diagnostic Pathway for Chronic Liver Disease
Clinical Management of primary hypertension
Prevention Diabetes.
Copyright © 2015 by the American Osteopathic Association.
Therapeutic Lifestyle
Delivery of the NHS Health Check by health trainers can improve conversion into uptake of lifestyle service Dr Ifeoma Onyia Public Health Consultant Halton.
Asymptomatic Abnormal LFTs NHS Lothian guideline
Diabetes Mellitus.
Cardiovascular System
National Cholesterol Education Program
Diabetes Health Status Report
Patients aged 85yrs and over
Monitoring in Type 2 Diabetes
Prevention Diabetes Dr Abir Youssef 29/11/2018.
Diabetes Dr. J. Antony Gagnon, Pharm.D., CDE, CAE
Rational Order of Laboratory Tests in Cardiovascular Diseases
Chapter 7 LIPIDS IN HEALTH & DISEASE
Asymptomatic Abnormal LFTs NHS Lothian guideline
Goals & Guidelines A summary of international guidelines for CHD
Obesity Eppie Habashi.
Section 6: Update on lipid treatment guidelines
ATP III Guidelines Benefit Beyond LDL-Lowering:
Specific Dyslipidemias: Very High LDL Cholesterol (>190 mg/dL)
Presentation transcript:

Repeat fasting lipid profile to confirm in 1-2 weeks NHS Lothian Primary Care Summary Guidance for the Investigation & Management of Hypertriglyceridaemia November 2017 A Guide to Best Practice in Lothian revised in line with 2016 updated NICE Guidelines Dr T Caparrotta, Dr S Jenks, Dr I MacIntyre, Dr J Malo, Prof S Maxwell, Dr E Morrison, Dr P Rae and Prof DJ Webb Triglycerides (TG) (mmol/L) Routinely measured as part of a full lipid profile to enable LDL calculation. TG testing in isolation is rarely indicated. Can be elevated on a non-fasting sample due to the presence of dietary TG, consider fasting sample. Very high TG levels e.g. >10mmol/L are associated with pancreatitis; increased morbidity and mortality independent of CVD risk. High TG are most commonly due to secondary causes e.g. poorly controlled diabetes mellitus, alcohol excess or medications. The relationship between TG and cardiovascular risk is unclear. Overall it is felt that raised TG still confer a small degree of additional risk. Raised TG e.g. >5mmol/L on a random sample Repeat fasting lipid profile to confirm in 1-2 weeks If fasting TG raised at >2.5 Assess & treat secondary causes† Give lifestyle & dietary advice* Repeat fasting lipid profile after above interventions Clinical assessment Check BP, measure weight/BMI, smoking status & alcohol intake Examine for any skin changes suggestive of a primary hyperlipidaemia Check TFTs, fasting blood glucose (click here for more information on the diagnostic work-up for diabetes), renal function, liver function, MCV and GGT † Consider any relevant secondary causes e.g. review medications Further tests as appropriate e.g. pregnancy test, urinalysis to check for proteinuria TG 2.5 – 4.49 Continue to treat any secondary causes Reinforce lifestyle advice Regular TG monitoring not required TG 4.5 – 10 Treat with a statin if at significant cardiovascular risk (based on usual criteria) If treatment is not started repeat TG in 1 month to confirm TG remain <10 TG >10 Refer to secondary care Optimise any secondary causes Consider starting a fibrate if not contra- indicated During treatment Repeat fasting lipid profile & ALT in 8 weeks No specific treatment target exists for TG at present In this group the main treatment aim is to transform a highly atherogenic lipid profile with moderately raised TG, high LDL and low HDL into a less atherogenic one If TG remain > 5 on statin treatment and the patient is at high cardiovascular risk we recommend specialist advice is obtained(preferably via e-mail) † Secondary causes of raised TG Alcohol excess Hypothyroidism Nephrotic syndrome/ renal disease Immunoglobulin excess Drugs (including thiazides, non-cardioselective beta blockers, oestrogens, tamoxifen, corticosteroids) Bulimia Pregnancy Obesity Insulin resistance Diabetes Metabolic syndrome Seek specialist advice If TG >10 TG 5–10 in a high cardiovascular risk patient not responding to statin treatment Suspected familial hyperlipidaemia Patients with significant hyperlipidaemia that is proving difficult to manage in primary care Refer urgently to secondary care those with TG >20 not caused by alcohol or poor glycaemic control * Lifestyle advice Weight loss, if appropriate Reduce or abstain from alcohol Dietary modification: reduce total calorie intake by minimizing intake of fats and carbohydrate increase intake of fish, especially oily fish Smoking cessation (smoking independently increases TG levels) Increase physical activity Clinic Specialist advice contact details Lipid Clinic, RIE RIE.LipidClinicAdvice@luht.scot.nhs.uk CVD risk clinic, WGH WGH.CardiovascRiskAdvice@luht.scot.nhs.uk Lipid clinic, SJH Tel: 01506 523 841 Lothian lipid guidelines Lothian Lipid Guidelines.pdf Version: 2, Approved: ADTC ‘17, Review date: 11/20